2026-09-21T06:58:41Zhttps://wakespace.lib.wfu.edu/server/oai/request

oai:null:10339/373092026-09-02T12:17:56Zcom_10339_14934col_10339_38132

Pinder, Tanya 2012-06-12T08:36:05Z 2013-06-12T08:30:11Z 2012 https://wakespace.lib.wfu.edu/handle/10339/37309 Prostate cancer is the most common non-skin cancer in American men. At the current time, there is no effective treatment for men with metastatic prostate cancer. Androgen ablation is the most successful systemic treatment for prostate cancer. However, the cancer eventually recurs as androgen-independent prostate cancer. Phosphoinositide 3-kinases (PI3Ks) are involved in several imperative cellular functions such as growth and survival; therefore, inhibition of PI3K induces apoptosis (programmed cell death) and suppresses tumor growth. Several compounds have been identified as PI3K inhibitors, e.g., wortmannin, LY294002, and, ZSTK474, but all have low selectivity. We have addressed the specificity of current PI3K inhibitors by developing PSA (prostate-specific antigen)-activated analogues of known PI3K inhibitors LY294002 and ZSTK474. en Wake Forest University LY294002 PI3K inhibitor ZSTK474 SYNTHESIS AND SCREENING OF PI3K INHIBITOR PRODRUGS FOR TREATMENT OF PROSTATE CANCER Dissertation Welker, Mark E. Kulik, George Alexander, Rebecca W. Colyer, Christa L. Wright, Marcus W. Chemistry 2013-06-12 restricted